Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Non-Current Deffered Revenue: 2023

  • Addex Therapeutics' Non-Current Deffered Revenue was N/A to $100,596 in Q4 2023 from the same period last year, while for Dec 2023 it was $100,596, marking a year-over-year change of. This contributed to the annual value of $99,355 for FY2023, which is N/A change from last year.
  • Per Addex Therapeutics' latest filing, its Non-Current Deffered Revenue stood at $100,596 for Q4 2023.
  • Addex Therapeutics' Non-Current Deffered Revenue's 5-year high stood at $100,596 during Q4 2023, with a 5-year trough of $100,596 in Q4 2023.
  • Over the past 1 years, Addex Therapeutics' median Non-Current Deffered Revenue value was $100,596 (recorded in 2023), while the average stood at $100,596.